3 months ago
MRK
AnalystsSteve ScalaSteve Scala's Stock Forecasts
AnalystsSteve Scala
Sectors:
Industries:
Analyst Ranking
Top 26%
#1337 out of 5256 analysts
Average Return
+13.4%
Win Rate
77%17 out of 22
Risk vs Reward
Poor
Good
Steve Scala's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +89.72% | $423.21 | $802.91 | 2023-05-23 - 2024-05-22 | Buy |
Eli Lilly & CoLLY | +58.60% | $369.29 | $585.68 | 2022-12-05 - 2023-12-04 | Buy |
Eli Lilly & CoLLY | +34.23% | $232.97 | $312.72 | 2021-06-24 - 2022-06-23 | Buy |
Royalty Pharma PLCRPRX | +27.03% | $38.81 | $49.30 | 2025-12-11 - 2026-04-20 | Strong Buy |
Eli Lilly & CoLLY | +22.98% | $151.18 | $185.92 | 2020-04-15 - 2021-04-15 | Buy |
Steve Scala Analyst Color
Get additional color on Steve Scala's coverage of popular stocks
4 months ago
RPRX
2 years ago
AZN
2 years ago
PFE
3 years ago
LLY
Steve Scala's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Merck & Co IncMRK | 2 | Hold | $120.00 | +2.48% | Maintains | 3 months ago |
Royalty Pharma PLCRPRX | 2 | Strong Buy | $45.00 | -8.72% | Maintains | 4 months ago |
Abbvie IncABBV | 10 | Strong Buy | $225.00 | N/A | Maintains | 2 years ago |
Bristol Myers Squibb CoBMY | 3 | Hold | $59.00 | N/A | Maintains | 2 years ago |
Astrazeneca PLCAZN | 1 | Strong Buy | $95.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 1 | Hold | $32.00 | N/A | Downgrades | 2 years ago |
Roche Holding LtdRHHBY | 3 | Hold | $40.00 | N/A | Maintains | 3 years ago |
Eli Lilly & CoLLY | 6 | Buy | $500.00 | N/A | Maintains | 3 years ago |
Eqrx IncEQRX | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Novartis AgNVS | 3 | Hold | $105.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.